{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T20:29:45Z","timestamp":1773692985081,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Addictive Behaviors"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.addbeh.2021.106943","type":"journal-article","created":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T11:39:27Z","timestamp":1617363567000},"page":"106943","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Should gabapentinoids be prescribed long-term for anxiety and other mental health conditions?"],"prefix":"10.1016","volume":"119","author":[{"given":"Mark Abie","family":"Horowitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kelleher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.addbeh.2021.106943_b0005","unstructured":"National Institute for Health and Clinical Excellence. CG113: Generalised anxiety disorder and panic disorder in adults: management. 2011. https:\/\/www.nice.org.uk\/guidance\/cg113\/chapter\/1-Guidance (accessed March 30, 2021)."},{"key":"10.1016\/j.addbeh.2021.106943_b0010","unstructured":"Public Health England. Dependence and withdrawal associated with some prescribed medicines. An evidence review. 2019. https:\/\/www.gov.uk\/government\/publications\/prescribed-medicines-review-report (accessed March 30, 2021)."},{"issue":"1","key":"10.1016\/j.addbeh.2021.106943_b0015","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/ijcp.12182","article-title":"Pregabalin is increasingly prescribed for neuropathic pain, generalised anxiety disorder and epilepsy but many patients discontinue treatment","volume":"68","author":"Wettermark","year":"2014","journal-title":"Int J Clin Pract"},{"issue":"2","key":"10.1016\/j.addbeh.2021.106943_b0020","doi-asserted-by":"crossref","first-page":"142","DOI":"10.24869\/psyd.2018.142","article-title":"On the addictive power of gabapentinoids: A mini-review","volume":"30","author":"Bonnet","year":"2018","journal-title":"Psychiatr Danub"},{"key":"10.1016\/j.addbeh.2021.106943_b0025","article-title":"Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: Population based cohort study in Sweden","volume":"365","author":"Molero","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.addbeh.2021.106943_b0030","unstructured":"Office for National Statistics. Deaths related to drug poisoning by selected substances. 2020. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/deaths\/datasets\/deathsrelatedtodrugpoisoningbyselectedsubstances (accessed Oct 26, 2020)."},{"issue":"9","key":"10.1016\/j.addbeh.2021.106943_b0035","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/add.13843","article-title":"Risk to heroin users of polydrug use of pregabalin or gabapentin","volume":"112","author":"Lyndon","year":"2017","journal-title":"Addiction"},{"key":"10.1016\/j.addbeh.2021.106943_b0040","doi-asserted-by":"crossref","unstructured":"Nahar, L. K., Murphy, K. G., & Paterson, S. (2019). Misuse and mortality related to gabapentin and pregabalin are being under-estimated: A two-year post-mortem population study. 43(7), 564\u2013570.","DOI":"10.1093\/jat\/bkz036"},{"key":"10.1016\/j.addbeh.2021.106943_b0045","unstructured":"Aurobindo Pharma. Pregabalin (SmPC). 2021. https:\/\/www.medicines.org.uk\/emc\/product\/7132\/smpc#gref (accessed Feb 1, 2021)."},{"key":"10.1016\/j.addbeh.2021.106943_b0050","unstructured":"Department of Health. Drug Misuse and Dependence: UK guidelines on clinical management. 2017."},{"issue":"3","key":"10.1016\/j.addbeh.2021.106943_b0055","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/1060028015620800","article-title":"Gabapentin: Abuse, Dependence, and Withdrawal","volume":"50","author":"Mersfelder","year":"2016","journal-title":"Ann Pharmacother"},{"issue":"10173","key":"10.1016\/j.addbeh.2021.106943_b0060","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0140-6736(18)31793-8","article-title":"Pharmacological treatments for generalised anxiety disorder: A systematic review and network meta-analysis","volume":"393","author":"Slee","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.addbeh.2021.106943_b0065","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.euroneuro.2017.08.430","article-title":"How addictive are gabapentin and pregabalin?","volume":"27","author":"Bonnet","year":"2017","journal-title":"A systematic review. Eur Neuropsychopharmacol"},{"issue":"8","key":"10.1016\/j.addbeh.2021.106943_b0070","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/j.1528-1167.2006.00607.x","article-title":"Experimental and Clinical Evidence for Loss of Effect (Tolerance) during Prolonged Treatment with Antiepileptic Drugs","volume":"47","author":"Loscher","year":"2006","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.addbeh.2021.106943_b0075","first-page":"17","article-title":"Benzodiazepines I: Upping the Care on Downers: The Evidence of Risks","volume":"7","author":"Guina","year":"2018","journal-title":"Benefits and Alternatives. J Clin Med"},{"issue":"1","key":"10.1016\/j.addbeh.2021.106943_b0080","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/YIC.0b013e3282f0f0d7","article-title":"Long-term efficacy of pregabalin in generalized anxiety disorder","volume":"23","author":"Feltner","year":"2008","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.addbeh.2021.106943_b0085","unstructured":"NICE. Chronic pain in over 16s: assessment and management. 2020 https:\/\/www.nice.org.uk\/guidance\/GID-NG10069\/documents\/draft-guideline."},{"key":"10.1016\/j.addbeh.2021.106943_b0090","unstructured":"EBM DataLab. OpenPrescribing.net. 2017. https:\/\/openprescribing.net\/chemical\/0408010AE\/ (accessed Oct 7, 2020)."},{"key":"10.1016\/j.addbeh.2021.106943_b0095","article-title":"Gabapentin Therapy in Psychiatric Disorders: A Systematic Review","volume":"17","author":"Berlin","year":"2015","journal-title":"Prim care companion CNS Disord"}],"container-title":["Addictive Behaviors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306460321001283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306460321001283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T18:46:13Z","timestamp":1759689973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306460321001283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":19,"alternative-id":["S0306460321001283"],"URL":"https:\/\/doi.org\/10.1016\/j.addbeh.2021.106943","relation":{},"ISSN":["0306-4603"],"issn-type":[{"value":"0306-4603","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Should gabapentinoids be prescribed long-term for anxiety and other mental health conditions?","name":"articletitle","label":"Article Title"},{"value":"Addictive Behaviors","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addbeh.2021.106943","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106943"}}